Nabriva Therapeutics plc filed its 10-K on Apr 17, 2023 for the period ending Dec 31, 2022. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | 0.00% | 0.00% | +9,900.00% |
2023 | Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 | CI |
2023 | Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index | CI |
1st Jan change | Capi. | |
---|---|---|
+9,900.00% | 323 | |
-2.72% | 103B | |
+1.40% | 95.28B | |
+1.46% | 22.15B | |
-15.90% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.01% | 16.05B | |
+5.03% | 13.68B | |
+33.36% | 12.17B |
- Stock Market
- Equities
- NBRVF Stock
- News Nabriva Therapeutics plc
- Nabriva Therapeutics plc Auditor Raises 'Going Concern' Doubt